Moomoo AIのまとめ
Mangoceuticals, Inc. reported financial results for the quarter ended March 31, 2024, with revenue reaching $214,095, a significant increase from $100,722 in the same period the previous year. The company's cost of revenues was $20,795, down from $23,753 year-on-year, while related party cost of revenues increased to $45,902 from $19,770. Gross profit for the quarter stood at $147,398, more than double the $57,199 reported in the prior year's quarter. Operating expenses totaled $2,515,015, with general and administrative expenses at $771,958, down from $1,297,271 in the previous year. The company also reported salary and benefits expenses of $293,209, advertising and marketing costs of $852,383, and investor relations expenses of $143,000. Stock-based compensation was $454,465. The net loss for the quarter was $2,367,617, a slight improvement from a net loss of $2,560,885 in the same quarter of the previous year. Mangoceuticals' business development included efforts to expand and grow operations, with plans to enhance its telemedicine platform, develop new products, and explore strategic acquisitions. The company's future plans involve continued investment in marketing and technology to attract new customers and expand product offerings.
Mangoceuticals, Inc. reported financial results for the quarter ended March 31, 2024, with revenue reaching $214,095, a significant increase from $100,722 in the same period the previous year. The company's cost of revenues was $20,795, down from $23,753 year-on-year, while related party cost of revenues increased to $45,902 from $19,770. Gross profit for the quarter stood at $147,398, more than double the $57,199 reported in the prior year's quarter. Operating expenses totaled $2,515,015, with general and administrative expenses at $771,958, down from $1,297,271 in the previous year. The company also reported salary and benefits expenses of $293,209, advertising and marketing costs of $852,383, and investor relations expenses of $143,000. Stock-based compensation was $454,465. The net loss for the quarter was $2,367,617, a slight improvement from a net loss of $2,560,885 in the same quarter of the previous year. Mangoceuticals' business development included efforts to expand and grow operations, with plans to enhance its telemedicine platform, develop new products, and explore strategic acquisitions. The company's future plans involve continued investment in marketing and technology to attract new customers and expand product offerings.
Mangoceuticals、Inc.は、2024年3月31日の四半期の財務結果を報告し、売上高は$214,095に達し、前年同期の$100,722から大幅に増加しました。売上原価は$20,795で、前年同期の$23,753から減少し、関係会社の売上原価は$45,902から$19,770に増加しました。四半期の粗利益は$147,398で、前年同期の報告された$57,199の倍以上です。営業費用は$2,515,015で、一般および管理費用が$771,958となり、前年の$1,297,271から減少しました。会社はまた、$293,209の給与および福利費、$852,383の広告およびマーケティング...すべて展開
Mangoceuticals、Inc.は、2024年3月31日の四半期の財務結果を報告し、売上高は$214,095に達し、前年同期の$100,722から大幅に増加しました。売上原価は$20,795で、前年同期の$23,753から減少し、関係会社の売上原価は$45,902から$19,770に増加しました。四半期の粗利益は$147,398で、前年同期の報告された$57,199の倍以上です。営業費用は$2,515,015で、一般および管理費用が$771,958となり、前年の$1,297,271から減少しました。会社はまた、$293,209の給与および福利費、$852,383の広告およびマーケティング費、$143,000の投資家関係費用を報告しました。ストックベースの報酬は$454,465でした。四半期の純損失は$2,367,617で、前年の同四半期の純損失$2,560,885からわずかに改善しました。Mangoceuticalsのビジネス開発には、テレメディシンプラットフォームの強化、新製品の開発、戦略的な買収の探索などの取り組みが含まれました。会社の将来計画には、新しい顧客の獲得と製品提供の拡大のために、マーケティングとテクノロジーへの継続的な投資が含まれます。
役に立った
役に立たない